Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit

Last Updated: Monday, December 19, 2022

In metastatic triple-negative breast cancer (mTNBC), consistent biomarkers of immune checkpoint inhibitor therapy benefit remain elusive. This study identified potential biomarkers of response to ICIs among patients with mTNBC, including high tumor mutational burden; presence of CD8+, CD4 memory T cells, follicular helper T cells, and M1 macrophages; and inflammatory gene expression pathways.

JCO Precision Oncology

Breast Cancer: Targets and Therapy

Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective

Expert Review of Anticancer Therapy

The role of immune checkpoint inhibition in triple negative breast cancer

Therapeutic Advances in Medical Oncology

Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: First observations from an interdisciplinary breast cancer centre in Germany

Breast Cancer: Basic and Clinical Research

Real-world survival and treatment regimens across first- to third-line treatment for advanced triple-negative breast cancer

The ASCO Post

Current management of and future possibilities for triple negative breast cancer

Breast Cancer: Basic and Clinical Research

Implementation of risk-stratified breast cancer prevention with a polygenic risk score test in clinical practice

Critical Reviews in Oncology/Hematology

Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey

Breast Cancer Research and Treatment

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer

European Journal of Cancer

Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort

ESMO Open

How I Treat Metastatic Triple-Negative Breast Cancer

Metastatic Triple-Negative Breast Cancer Resource Center

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit

Breast Cancer: Targets and Therapy

Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective

Expert Review of Anticancer Therapy

The role of immune checkpoint inhibition in triple negative breast cancer

Therapeutic Advances in Medical Oncology

Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: First observations from an interdisciplinary breast cancer centre in Germany

Breast Cancer: Basic and Clinical Research

Real-world survival and treatment regimens across first- to third-line treatment for advanced triple-negative breast cancer

The ASCO Post

Current management of and future possibilities for triple negative breast cancer

Breast Cancer: Basic and Clinical Research

Implementation of risk-stratified breast cancer prevention with a polygenic risk score test in clinical practice

Critical Reviews in Oncology/Hematology

Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey

Breast Cancer Research and Treatment

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer

European Journal of Cancer

Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort

ESMO Open

How I Treat Metastatic Triple-Negative Breast Cancer

Patient With Lung Metastasis and HER2-Low Status: Evolving Treatment Options

Treatment of a Patient With AML and mTNBC

Fast Facts #6: Immunotherapy and Endocrinopathies